Stephens Initiates Coverage on Cytek Biosciences (NASDAQ:CTKB)

Stephens assumed coverage on shares of Cytek Biosciences (NASDAQ:CTKB – Free Report) in a report released on Thursday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $9.00 price objective on the stock. Several other brokerages have also recently issued reports on CTKB. Morgan Stanley lowered their target price on shares of […]

Leave a Reply

Your email address will not be published.

Previous post Marathon Petroleum (NYSE:MPC) Upgraded to “Overweight” at Wells Fargo & Company
Next post Exact Sciences (NASDAQ:EXAS) Earns Buy Rating from Analysts at Guggenheim